Member Info for LovableLumax

Who knows Mirriad might have a strategic investor who will take shares to get them through the audit or may really accelerate revenue growth, who knows but the notion that directors are in a closed period due to new clients is nonsense. Shopify was secured last year and wasn't material so no RNS which is obvious given the paltry revenues and looking at the KPIs you can see the number of campaigns and brands represented which shows they're worth very little. There have been months without material RNSs and the reason this BOD has never bought in the open market is not due to being unable to. The next month or so make or break.

I don’t think they’re having issues and I believe it when we were old there are several interested parties all those months ago. Negotiations always complex, 2 businesses some may want both others may not. I suspect news imminent and I bet more than enough cash to next year so if P1b data as good we many hope Avacta will hold the cards and get the deal it wants. 50p raise painful but I believe once DX sold we will regain momentum ahead of P1b. I also suspect if data really superb we will not get to P2. I’d rather a buy out after P1b and yeah maybe less than during P2 but get this amazing platforms into BP ASAP to help people.

An exciting few months ahead after a poor 12 months share price-wise but rich data further underpinning the platform.

*I mean we has seen a very ill patient seeing superb results after a mere 2 cycles

Wyn - This is hand to mouth stuff every 12-18 months. Any solution to break this cycle would have already been put in place.

My hope is DX sale coupled with existing cash of say £17m will mean no cash needed until next year and P-b data will mean the next raise will be on superb terms unless of course the data so good FDA want to help SGC or STS patients or indeed Avacta is taken over. I mean we has a very ill patient seeing supper results after a mere 2 cycles and an ongoing response thereafter (after dosing finished due to max cumulative reached).

Christ I was merely pointing out the obvious that a higher share pride does matter when we have a quarterly conversion so ideally get it higher to limit dilution which is good for holders and will likely attract more higher end investors with deep pockets which could ensure all IP retained. We’re going round in circles so best to move on.

Ice, no disrespect but it’s irrelevant what we care about.

Sophisticated investors care about dilution and if we don't want to pen deals as we as don't want to part with amazing IP we may well want to attract such investors to accumulate data and get to the point of a complete takeover. 6103 looks like it could supersede all else so why would we do a deal on that which could render most else redundant. Improve the share price, fewer shares converted, no DX and attract proper investors.

Also, to spell it out if we get the share price really high after recalculation and only needed 2m shares a quarter and say the share price slides and we need 8m that's a massive difference. 32m or nearly 10% pa or 2% pa. Anyway, science is sound and now to create shareholder value and limit dilution.

Ice perhaps you don’t understand how quarterly conversions work. FYI a higher share pride means fewer shares converted so less dilution and more attractive to other investors. Part of the CEo role is to create sustained shareholder value. I am sure all will look a lot better ahead of audit sign off,

Avacta is struggling sustain any increase in share price due to HCI and all knowing cash is needed. A DX sale of both businesses for circa £20m means the share price can build and that will mean fewer conversion shares needed and less of a drag. Many negative on Avacta said they'd be no efficacy in a safety trial and there has been and now the criticism is there's not enough. I mean the fact there are many cases of lives being extended with disease stabilised or regressed and some once dosing has stopped is remarkable. P1b will likely knock it out of the park and that being the case there will be, IMO, finally genuine optionality. Could be a very quick approval route given SGC has no standard of care so a low bar. Anyway I hope once DX sold they need to lay out a clear roadmap which I reckon will enable a share price recovery before P1b data (and we may get some emerging data before full read out) and then who knows could be enough efficacy data in 90 patients (30 in each arm) for a full takeover or superb deals on Avacta terms. Data means recruitment should be fast. A reminder -

https://www.alainelkanninterviews.com/virgilio-sacchini-4/

I expect DX sale will enable audit sign off and P1b results will be superb (on naive rumours and dox sensitive) and we can then look to raise a lot of money on much better terms.

Rah on X-

The market is still yet to cotton on to the significance of #AVCT delivering straight dox.

Straight dox. Not a novel compound.

It’s why the FDA route will likely be eased (now safety is proven) but also why the risk of failure is far lower than a normal P1b drug.

So as you say, what AVCT sits on is not just a solution which delivers an ‘old’ drug (thus making the regulatory path far easier) but one which is also behaving in a different way because of the impact it’s causing on the stroma/TME etc.

The impact of taking an old drug and changing the way it inhibits (without actually changing its pre-cleavage chemical structure) is an incredibly exciting proposition, given the FDA views this as ‘just dox’ from a chemical/regulatory perspective.

We spent so much time (pre-efficacy results) talking about the risks of tumour evasion and the mechanism dox builds to promote resistance.

We’re now talking about how AVA6000 manages to kill cancer after the dosing stops…

https://x.com/rah00084/status/1885982216808788229?s=46

If the sale of the DX businesses mean we have sufficient cash to have audit signed off so are fine to Q2 next year I would rather not pay off Heights. P1b data will surely be blockbuster and finally give us options aplenty. If we lay out a roadmap with sufficient cash to next year the share price will recover and fewer shares needed each Q and as before little to no drag due to Heights. Then the science can again take centre stage. Next few RNSs will hopefully regain momentum.

Guys these ads are worth peanuts to mirriad. RNSs cost money. If mirriad was to RNS every campaign or new client they’d lose even more money. Remember in H1 2024 they worked with 85 supply partners with 25 advertisers who ran campaigns and the revenue was £390k so each advertiser spent on average around £15k. It’s small fry hence not material so no RNSs. Of course directors could buy, they only do so in raises. Fact.

A median progression-free survival (PFS) of 13.2 months was seen in patients randomised to Enhertu compared to 8.1 months in those randomised to chemotherapy. The confirmed objective response rate (ORR) in the overall trial population was 62.6% for Enhertu versus 34.4% for chemotherapy.

Https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et.html

In the trial, Enhertu showed a 36% reduction in the risk of disease progression or death versus chemotherapy (hazard ratio [HR] 0.64; 95% confidence interval [CI]: 0.54-0.76; p

In the trial, Enhertu showed a 36% reduction in the risk of disease progression or death versus chemotherapy (hazard ratio [HR] 0.64; 95% confidence interval [CI]: 0.54-0.76; p

I believe regulated RNSs rather than hearsay. From April AR RNS -

Based on these indications, the Directors are confident that the Company will have sufficient funds to continue to meet its liabilities as they fall due for at least twelve months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.

Nonsense it's 12 months from the audit sign off (April). I reckon with DX sale they will have some £30m which will be enough. A guess but we will know as they will surely lay out the position once DX sold

I know I said I'd post once the next RNS was published so apologies if this isn't well received by the resident rampers. Apparently the creep Phevs won't read it but I hope others consider it fair enough.

I keep on hearing US investors are accumulating. What's interesting is since the placing TR1s we have had 4 which have been shareholders reducing their holdings. Long periods without material RNSs so directors could have bought in the open market but haven't. LOTM has highlighted the large numbers held by 4 posters here. There are 4 on the BoD and they hold 1/4 of the holding 4 posters on here have. Stephan has been CEO for several years and has a mere 4.3m. What's also interesting is the Chairman who put his money where his mouth is in the 'mates rates' raise is an exec chair yet we haven't heard from him in any updates (interim or TU). I bet, like Milner he feels he wasn't given the complete truth from Stephan. £4m revenue guidance turns into £1m which funnily enough is 1/4 of guidance and as mentioned the BoD has 1/4 of the shares of 4 here (BoD has 16,150,266 shares). To me that's another red flag, lack of skin in the game but taking large, unjustified salaries.

To summarise since the huge drop in share price not only do we not have any TR1s of buys 75%+ below mates rates raise we have large investors reducing. The only significant buying it seems is from retail. 4 holders here have over 4 times the number of shares the 4 directors have.

LOTM trying to rewrite history. You didn’t even know

What a going concern was FFS. Anyway, I’ve always said they’ll need 12 months cash to get audit signed off and they will. That doesn’t mean 12 months of their total cost base but 12 months cash on the bank to ensure they can last for 12 months. My bet is they will need at least £5m but I’d be surprised if it’s not £6m. If I’m way out and they only need say £3m I’ll be surprised and happy to say I was wrong and apologise.

That’s if from me until the next RNS. Have a good weekend and Phevs stay away from the playgrounds.

Why should I declare anything? It’s a BB FFS. I’m not done saddo like you who asks. - what made you invest here, how did you hear About mirriad? Odd.

Pretty much everything I’ve posted since last March has come up trumps.

As far as credibility goes the creep Phevs sold out twice and ramped before and you ramped this on other BBs and then apologised.

I’m off to the pub. Don’t reply and I can enjoy my beers